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Although ampicillin is the most commonly used drug in neonates, developmental pharmacokinetic (PK) data to guide dosing are
lacking. Ampicillin is primarily renally eliminated, and developmental changes are expected to influence PK. We conducted an
open-label, multicenter, opportunistic, prospective PK study of ampicillin in neonates stratified by gestational age (GA) (<34 or
>34 weeks) and postnatal age (PNA) (<7 or >7 days). Drug concentrations were measured by tandem mass spectrometry. PK
data were analyzed using population nonlinear mixed-effects modeling in NONMEM 7.2. Monte Carlo simulations were con-
ducted to determine the probability of target attainment for the time in which the total steady-state ampicillin concentrations
remained above the MIC (T>MIC) for 50%, 75%, and 100% of the dosing interval. A total of 142 PK samples from 73 neonates
were analyzed (median [range] GA, 36 [24 to 41] weeks; PNA, 5 [0 to 25] days). The median ampicillin dose was 200 (100 to 350)
mg/kg/day. Postmenstrual age and serum creatinine were covariates for ampicillin clearance (CL). A simplified dosing regimen
of 50 mg/kg every 12 h for GA of <34 weeks and PNA of <7 days, 75 mg/kg every 12 h for GA of <34 weeks and PNA of >8 and
<28 days, and 50 mg/kg every 8 h for GA of >34 weeks and PNA of <28 days achieved the prespecified surrogate efficacy target
in 90% of simulated subjects. Ampicillin CL was associated with neonatal development. A simplified dosing regimen stratified by
GA and PNA achieves the desired surrogate therapeutic target in the vast majority of neonates.
Ampicillin is the most commonly administered medication inthe neonatal intensive care unit (NICU), yet its pharmacoki-
netics (PK) and safety in neonates are poorly described, and mul-
tiple dosing reference guides provide a variety of dosing recom-
mendations based on limited PK data (see Table S1 in the
supplemental material). The PK of ampicillin have been studied in
children and adults (1–14), but data on dosing in the neonatal
population are sparse. Current dosing regimens take into account
the gestational age (GA)- and postmenstrual age (PMA)-related
variation in renal drug clearance and recommend lower doses and
less frequent dosing in the most premature neonates (1). How-
ever, the available data in the literature are insufficient to support
dosing of ampicillin in the most extremely premature neonates
(GA of 32 weeks at birth).
Given the inherent difficulties with multiple blood draws to
acquire blood samples in neonates, capitalizing on standard-of-
care procedures (such as biological sample collection from
neonates already receiving drugs per routine medical care) has
produced meaningful PK data, resulting in improved dosing rec-
ommendations for neonates (15). Opportunistic study designs of-
fer an advantage over traditional PK studies given the low risk to
participants and higher enrollment rates in a very difficult-to-
study population such as neonates. However, opportunistic stud-
ies can be limited by the type and quantity of data collected, as well
as by the reliability of standard-of-care procedures to generate
data used for analysis. Exploring the utility of opportunistic PK
study designs is imperative for neonates given recent legislation
mandating studies in this population (16).
Using an opportunistic design, this study sought to character-
ize the developmental PK of ampicillin prescribed per standard of
care to neonates across a wide age spectrum and to compare the
pharmacodynamic (PD) target attainments of various dosing
strategies.
MATERIALS AND METHODS
Study design. This prospective, multicenter (n  9) trial was conducted
under the PK of Understudied Drugs Administered to Children per Stan-
dard of Care Study (POPS) (protocol NICHD-2011-POP01) in the Pedi-
atric Trials Network (PTN). This protocol enrolled children 21 years of
age receiving drugs per routine medical care. The data presented here were
compiled from neonates receiving ampicillin. The protocol was reviewed
and approved by the institutional review board of each participating in-
stitution. The guardian provided informed consent. Neonates were strat-
ified by postnatal age (PNA) and GA (Table 1). The ampicillin dosing
regimen, PK sampling, and demographic information (age, sex, race or
ethnicity, GA at birth, birth weight, and actual weight) were recorded in
an electronic database. Ampicillin dosing information for up to 8 doses
prior to the first sampling dose was recorded. The following laboratory
values were collected, if available, within 24 h before or after the dose of
ampicillin closest to the time of biological sample collection: serum cre-
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atinine (SCR), plasma albumin, aspartate aminotransferase, alanine ami-
notransferase, and bilirubin (total and direct). Subjects were enrolled in
the study for up to 90 days.
A maximum of 10 research-only blood samples per subject was al-
lowed in our study. A PK sampling scheme was employed such that no
more than 2 ml/kg was obtained from each subject within a 90-day period.
Participating sites were encouraged to collect biological samples oppor-
tunistically; thus, PK samples were obtained at the time of clinical labora-
tory evaluations per standard of care. However, the option to consent to
sample collection for research purposes was given to the parent/guardian
of the participating infant. PK sampling windows were provided to the
sites as guidance for timing of PK sampling based on frequency of drug
administration (see Table S2 in the supplemental material). Samples were
stored frozen until ampicillin concentrations could be determined at the
central laboratory. Plasma samples collected as part of this study were sent
to a central laboratory for drug concentration measurements. A validated
assay to measure ampicillin concentrations was performed at a central lab,
OpAns Laboratory (Durham, NC), using a validated bioanalytical high-
pressure liquid chromatography-tandem mass spectrometry (HPLC-MS/
MS) assay. The validated range of this method for ampicillin based on 10
l of human plasma was 0.05 to 50 g/ml. Quality controls were nominal
concentrations of ampicillin in human plasma at 0.06, 4.0, and 40 g/ml.
The lower limit of quantification (LLOQ) was established using 5 quality
control samples, independent of calibration standards. In addition, the
lowest standard on the calibration curve was found to meet the following
criteria for each validation run: the analyte response was at least 5 times
the response compared with blank responses (i.e., signal-to-noise ratio of
5), and the analyte peak (response) was identifiable, discrete, and repro-
ducible with a precision (coefficient of variation [CV]) of 20% and an
accuracy of 80 to 120%. The LLOQ was defined by the lowest concentra-
tion on the standard curve and should not be confused with the limit of
detection and/or the low quality control sample. The highest standard
defined the upper limit of quantification.
PK analysis. PK models for ampicillin concentration data were ex-
plored by nonlinear mixed-effects modeling using NONMEM 7.2 (Icon,
Dublin, Ireland). Appropriate compartmental models were examined,
and between-subject variability on model parameters was explored. Data
were fitted to a 1-compartment model (ADVAN1 TRANS2) with the
first-order conditional estimation method with interaction (FOCE-I).
Proportional and additive residual error models were explored. Diagnos-
tic plots were used to assess the appropriateness of this structure for the
base and final models.
The investigation of the relationship between potential covariates and
PK parameters proceeded by estimating the base population PK model,
which included weight, with the generation of the Bayesian individual PK
parameters (e.g., clearance [CL] and volume [V]). With these individual
parameter estimates, their deviations from the typical population param-
eter values were also generated, i.e., individual subject ETAs (). Next,
graphical assessment of the relationships between PK parameters and po-
tential covariates was performed by plotting ETAs versus potential clini-
cally relevant covariates. Clinical variables were evaluated as potential
covariates for PK parameters using a univariate screen in NONMEM fol-
lowed by a multivariate assessment of the final population PK model. The
following potential covariates were included in the univariate analysis:
SCR, days of life (DOL) (which was PNA plus 1), GA, PMA, and birth
weight. The construction of the final population PK model was based on
NONMEM univariate and multivariate analyses with graphical explora-
tion. During the model-building process, potential covariates that re-
duced the objective function by more than 3.84 (P  0.05) were planned
for inclusion in the subsequent multivariate analysis. A forward inclusion
approach with backwards elimination was planned for the multivariate
step, and a reduction of 7.88 (P  0.005) was required for retention of a
covariate in the final model.
Standard model diagnostic plots and procedures were used to evaluate
model appropriateness. Empirical Bayesian estimates of individual sub-
ject PK parameters were generated from the final model. Model reli-
ability was examined by visual predictive check (VPC) and 1,000-set
bootstrapping procedures using WINGS for NONMEM. The model
was considered reliable if the parameter estimates were within the 95%
confidence intervals.
TABLE 1 Demographic characteristicsa
Parameter
Value for the indicated gestational age (wk) and PNA (days)
Total
34 34
7 8–28 7 8–28
Group no. 1 2 3 4
n 21 7 27 18 73
Postnatal age (days) at day of first plasma PK sample
Mean (SD) 2.6 (2.3) 15.4 (4.0) 2.9 (2.6) 13.4 (5.4) 6.6 (6.4)
Median (minimum, maximum) 1.0 (0.0, 7.0) 16.0 (9.0, 21.0) 2.0 (0.0, 7.0) 12.5 (8.0, 25.0) 5.0 (0.0, 25.0)
Gestational age (wk)
Mean (SD) 30.3 (3.4) 26.9 (2.5) 38.2 (2.0) 38.4 (1.8) 34.9 (5.0)
Median (minimum, maximum) 32.3 (24.0, 34.0) 26.1 (25.0, 32.0) 38.0 (34.0, 41.0) 38.8 (35.0, 41.0) 36.1 (24.0, 41.0)
No. (%) male 9 (43) 3 (43) 18 (67) 8 (44) 38 (52)
Ethnicity, no. (%)
Hispanic or Latino 3 (14) 1 (14) 6 (22) 3 (16) 13 (18)
Not Hispanic or Latino 18 (86) 5 (71) 19 (70) 14 (78) 56 (77)
Not reported 0 1 (14) 2 (7) 1 (6) 4 (6)
Race, no. (%)
Black 4 (19) 3 (43) 3 (11) 2 (11) 12 (16)
White 16 (76) 3 (43) 23 (85) 14 (78) 56 (77)
Not reported 0 0 0 1 (6) 1 (1)
Other 1 (5) 1 (14) 0 1 (6) 3 (4)
a PK, pharmacokinetic; PNA, postnatal age.
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Analysis of surrogate pharmacodynamic endpoint using Monte
Carlo simulations. The PD target most correlated to maximal bacteri-
cidal activity for beta-lactams is the time in which free drug concentra-
tions remain above the MIC (TMIC) (17). The total, rather than free,
drug concentration was used in this study due to low protein binding of
ampicillin (10%) reported in neonates (18). Listeria monocytogenes and
Escherichia coli (with ampicillin MIC90s of 2 g/ml and 8 g/ml,
respectively, for susceptible isolates) can cause severe and fatal infections
in neonates. Streptococci are also common pathogens in neonates but are
very sensitive to ampicillin, with MIC90s of 0.5 g/ml. Complete anal-
yses were conducted to determine the probability of target attainment for
achieving steady-state trough concentrations at 50%, 75%, and 100%
TMIC at MICs of 2 and 8 g/ml.
Monte Carlo simulations were performed using the final population
PK model to determine the distribution of steady-state ampicillin concen-
trations from the “typical” dose selected by clinicians for each age group in
this study. The typical dose by age group (groups 1 to 4 as described in
Table 1) was determined by dividing the average total daily dose for the
group by the median dosing interval, rounded to the nearest 25 mg/kg.
For groups 1 and 2, this was 100 mg/kg every 12 h; for group 3, 75 mg/kg
every 8 h; and for group 4,100 mg/kg every 8 h.
In addition, simulations were performed using the dose recommen-
dations from references that are commonly used for neonatal doses: Neo-
fax (1) and Harriet Lane (19). Based on the relatively high concentrations
seen with the typical dose in the current study, a lower dosing strategy was
also evaluated. This revised dosing regimen was as follows: group 1, 50
mg/kg every 12 h; group 2, 75 mg/kg every 12 h; group 3, 50 mg/kg every
8 h; and group 4, 75 mg/kg every 8 h. The derivation of this optimal dosing
regimen was based on achieving steady-state trough concentrations in
90% of the simulated participants at an MIC of 8 g/ml. Simulations
were performed to encompass the full range of GA and PNA across all 4
groups.
A total of 1,920 virtual subjects, 480 in each age group, were included
at GAs of 24, 26, 28, 30, 32, 34, 35, 36, 37, 38, 39, and 40 weeks and PNAs
of 1, 3, 7, 10 14, 21, and 28 days. The current weight (kg) (WTKG) and
SCR used for each cohort were from a prior trial in premature infants (20).
An additional SCR variability of 30% (beyond fixed effects of GA and
PNA) was included during the NONMEM simulation by including a ran-
dom effect (ETA) on SCR with a variance (OMEGA) value of 0.09 (30%
CV). Medians and 95% confidence intervals were generated for the
steady-state total concentration-time profiles of each age group using the
various dosing strategies.
Statistical analysis. For continuous variables, descriptive statistics in-
cluded number of observations, mean, standard deviation, median, min-
imum, and maximum value. Discrete-variable summaries included
counts and proportions. Except for the PK modeling, data were analyzed
using SAS software, version 9.2 or later (SAS, Cary, NC).
RESULTS
A total of 75 participants provided consent for the study, were
enrolled based on PNA and GA, and had available PK samples. Of
the 75 participants, the indications for ampicillin included pre-
sumed or confirmed infection (n  38), sepsis (n  31), necrotiz-
ing enterocolitis (n  2), abdominal procedure (n  2), meco-
nium ileus with peritonitis (n  1), and pneumonia (n  1). PK
samples were collected opportunistically at times when blood
samples were collected for biochemical analysis, unless the guard-
ian consented to allow extra blood draws for research purposes,
which occurred for 28 (37%) of these participants. The first par-
ticipant was enrolled in February 2012, and the last participant
completed the study in August 2012. The demographic character-
istics are summarized in Table 1. One hundred sixty available
plasma PK samples were collected from the 75 participants, which
is an average of 2.1 per participant. Seventeen (23%) participants
had more than 2 samples collected.
Of the 75 participants, 2 were excluded for the following rea-
sons: (i) one subject had only one concentration that was below
the quantitative level (BQL), and PNA at the time of the first PK
sample was beyond the 28-day threshold (specifically, 30 days),
and (ii) another subject had a suspected error in dosing history





(mg/kg)a Dosing interval Typical POPSb dose
1 21 200 (161–303) 100 (81–109) 19% every 8 h, 81% every 12 h 100 mg/kg every 12 h
2 7 185 (113–194) 93 (57–97) 100% every 12 h 100 mg/kg every 12 h
3 27 218 (100–307) 100 (43–102) 59% every 8 h, 41% every 12 h 75 mg/kg every q 8 h
4 18 282 (184–350) 92 (46–100) 44% every 6 h, 28% every 8 h, 28% every 12 h 100 mg/kg every 8 h
Overall 73 200 (100–350) 98 (43–109) 11% every 6 h, 34% every 8 h, 55% every 12 h 100 mg/kg every 12 h
a Numbers represent median (range).
b POPS, NIH-funded study supporting this work that focuses on pharmacokinetics of understudied drugs administered to children per standard of care.





function from base model
V (base model) V  V · WTKG 1,284
CL (base model) CL  CL · WTKG 1,284
Birth wt CL  CL · WTKG · (BW/2,500)(2),BW 1,284 0
DOL CL  CL · WTKG · (DOL/7)(2),DOL 1,278 	6.108
GA CL  CL · WTKG · (GA/36)(2).GA 1,257 	26.81
PMA CL  CL · WTKG · (PMA/37)(2),PMA 1,251 	33.34
SCR CL  CL · WTKG · (0.6/SCR)(2),SCR 1,249 	34.85
SCR, PMA (final) CL  CL · WTKG · (0.6/SCR)(2),SCR · (PMA/37)(2),PMA 1,229 	55.19
a V, volume; WTKG,  weight in kg; CL, clearance; BW, birth weight; DOL, days of life (defined as postnatal age 
 1 day); GA, gestational age; PMA, postmenstrual age; SCR,
serum creatinine.
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(i.e., 10 mg for 1,290 g or 7.8 mg/kg) with a high observed con-
centration. Fourteen (9%) of 156 samples from the 73 remaining
participants were excluded: 6 samples were BQL and were thought
to be unreliable given the time after dose; 5 participants had levels
drawn after 24 h, which, given the dosing interval, were deemed to
not be reliable; 1 participant had a sample drawn during infusion
or flush; 1 sample was thought to be contaminated; and 1 partic-
ipant had a sample drawn after a one-time intramuscular admin-
istration.
A total of 73 participants with 142 observed drug concentra-
tions were included in the PK analysis. The median (range) ampi-
cillin dosing prescribed initially as standard of care for these 73
participants was 200 (100 to 350) mg/kg/day, administered every 6
to 12 h (Table 2). The median (range) time of PK sampling in
neonates with useable ampicillin concentration data was 4.8 (0.2
to 15.2) hours after the most recent dose, and the median (range)
observed concentration was 123 (0.85 to 464) g/ml. Collection of
blood for PK samples was relatively consistent throughout the
dosing intervals. Of the 142 measured samples, SCR values were
available within 2 days of the PK sample date for 109 (77%) of the
samples. Of the 73 participants, 24 had at least 1 SCR drawn in the
first 3 days of life.
The univariate screen using a 1-compartment population
PK model identified SCR and PMA as potential covariates for
CL and none for V (Table 3). The final model used the FOCE-I,
and the explicit formulas for the typical values of V and CL were
V (liters)  (1) · WTKG and CL (liters/h)  (2) · WTKG · (0.6/
SCR)(3)(PMA/37)(4), where (1)  0. 399, (2)  0.078, (3) 
0.428, and (4)  1.34. WTKG was weight (kg), SCR was serum
creatinine (mg/dl), and PMA was postmenstrual age (weeks). The
between-subject variability for CL was 23%, and the residual vari-
ability was 34%. The estimated values for the population PK pa-
rameters, covariate, and variances, along with the standard errors
of these estimates, bootstrap medians, and 95% confidence inter-
vals for these values, are listed in Table 4. The ETA shrinkage value
for CL was 21%, while the EPS shrinkage value for CL was 13%. In
an attempt to further refine our final PK model by replacing PMA
for GA and PNA as covariates (along with WTKG and SCR), the
objective function value did not improve, and hence our final PK
model was retained.
Individual subject post hoc CL estimates using the final model
appeared to increase with GA and PNA, as reflected by increasing
CL with each group (i.e., group 1 had the lowest CL and group 4
the highest) (Table 5). The half-life decreased with increasing both
components of PMA, GA and PNA, as would be expected with the
increasing CL when V was constant (Fig. 1). The goodness-of-fit
plots demonstrated that the model generally fit the observed con-
centrations for both the population and the individual (Fig. 2).
The post hoc Bayesian population estimates for V and CL were
similar to the median bootstrap analysis values and were within
the 95% confidence intervals obtained from the bootstrap analysis
(Table 4). One hundred percent of the bootstrap data sets con-
verged to 3 significant digits. The medians of bootstrap fixed-
effects parameter estimates were within 1.5% of population esti-
mates from the original data set for all parameters. The VPC using
individual time points indicated that the model adequately de-
scribed the data; 29% of the observations fell outside the 90%
prediction interval (Fig. 3).
Using the PD surrogate of 100% TMIC, all standard-of-care
ampicillin doses used in this study achieved predicted trough con-
centrations at steady state of 2 g/ml in 100% of participants;
100% of participants in groups 1 and 2 and 89% in groups 3 and 4
had predicted trough concentrations of 8 g/ml. All partici-
pants in groups 3 and 4 with trough concentrations of 8 g/ml
were dosed every 12 h compared to every 8 h.
Because of variability in the primary caregiver’s dose selection,
we evaluated standardized dosing using Monte Carlo simulations.
Based on the Monte Carlo simulations, 97% of virtual partici-
pants in all 4 age groups (at typical POPS doses listed in Table 2)
achieved 100% TMIC at an MIC of 8 g/ml (Table 6). In con-
TABLE 4 Final pharmacokinetic model parametersa
Parameter Symbol Point estimate % RSE
95% Bootstrap confidence interval
2.5% Median 97.5%
CL (2) 0.078 4.37 0.071 0.077 0.084
V (1) 0.399 6.34 0.350 0.398 0.452
CL, SCR (2),SCR 0.428 21.40 0.235 0.433 0.639
CL, PMA (2),PMA 1.34 23.73 0.651 1.31 1.96
CL interindividual variability (CV, %) 2CL 22.8 0.07 12.1 21.9 28.7
Residual variability (CV, %) 2 33.9 0.08 26.6 33.5 41.4
a CL, clearance (liters/h); V, volume (liters); SCR, serum creatinine (mg/dl); PMA, postmenstrual age (weeks); CV, coefficient of variation; RSE, relative standard error.
TABLE 5 Individual empirical Bayesian post hoc parameter estimatesa
Group n Clearance (liters/h/kg) Volume (liters/kg) Half-life (h)
Steady-state concn (g/ml)
Minimum Maximum
1 21 0.055 (0.03–0.07) 0.40 (0.40–0.40) 5.0 (3.9–9.4) 77 (36–320) 318 (244–563)
2 7 0.070 (0.03–0.07) 0.40 (0.40–0.41) 4.0 (3.8–8.3) 33 (21–145) 266 (159–368)
3 27 0.086 (0.04–0.13) 0.40 (0.40–0.40) 3.2 (2.2–6.2) 48 (5–173) 274 (127–413)
4 18 0.11 (0.06–0.13) 0.40 (0.40–0.41) 2.4 (2.1–4.7) 28 (5–129) 246 (138–203)
Overall 73 0.072 (0.03–0.13) 0.40 (0.40–0.41) 3.3 (2.1–9.4) 47 (5–320) 281 (127–563)
a All values are medians and ranges.
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trast, 10% of simulated subjects in at least one group failed to meet
the surrogate PD target of 100% TMIC at an MIC of 8 g/ml
when dosing recommendations found in pediatric guidelines
were used (Table 6). With the goal of achieving trough concentra-
tions of 8 g/ml in 90% of the simulated subjects, we simpli-
fied the dosing regimens from several references and devised an
optimal GA- and PNA-based dosing regimen for ampicillin (Ta-
ble 7). Although PMA was the covariate in our final PK model, we
replaced it with GA and PNA in streamlining the dosing regimens,
as these variables are easier to integrate into practical dosing
guidelines for clinical practice. Analysis of PD target attainment
using PMA-based dosing demonstrated results similar to those for
GA- and PNA-based dosing.
DISCUSSION
Ampicillin is a commonly used drug in neonates. However, the
insufficient PK studies (especially in very premature neonates),
coupled with the lack of uniformity in dosing regimens (which are
based on GA, PNA, weight, and PMA in pediatric dosing compen-
diums [see Table S1 in the supplemental material]), have led to
confusion on optimal drug dosing in this vulnerable population.
Early pharmacological studies of serum and cerebrospinal fluid
drug concentrations after intramuscular injection of ampicillin in
term and preterm (2,500 g) neonates were performed between
1967 and 1974. These studies included a combined total of 156
neonates (GA not specified) and showed that the serum half-life of
ampicillin decreases rapidly in the first 2 weeks of life as a result of
increasing drug clearance. The doses studied ranged from 25 to
150 mg/kg administered every 8 to 12 h according to PNA (2, 4, 8).
In a recent study comparing clinical efficacies of ampicillin and
penicillin in combination with gentamicin therapy for early-onset
sepsis in infants (including GA of 26 weeks), both were well
tolerated, with no difference in adverse events or laboratory ab-
normalities. However, the focus of this study was clinical effective-
ness comparison and not safety profiling (9).
A strength of the present study was its opportunistic design,
which capitalized on obtaining samples drawn at the same time
as when blood samples were collected for biochemical analysis
in neonates on drugs per routine medical care. Preliminary
data obtained through opportunistic studies have served in the
design of phase I to III trials in children. For example, through
the infrastructure of the Pediatric Pharmacology Research Unit
funded by the National Institutes of Health, Wade et al. ob-
tained timed and scavenged plasma samples to characterize the
PK of fluconazole in premature neonates (15). This PK analysis
FIG 1 Clearance (A) and half-life (B) versus postmenstrual age.
FIG 2 Observed versus population (A) and individual (B) predictions, final model.
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led to the dose selection for a phase III randomized, placebo-
controlled trial of fluconazole prophylaxis in premature neonates
(clinicaltrials.gov, NCT00734539). In our large opportunistic
study, we evaluated the population PK of ampicillin in 73 neo-
nates as young as 24 weeks of gestation and up to 28 days PNA.
This broad age spectrum enabled the construction of a population
PK model that incorporated developmental changes, including
age-related alterations in body composition and acquisition of
renal function, which occurs during the first month of life. Nota-
bly, some developmental processes that affect drug PK may not
occur linearly with age. In fact, the most striking changes in a
drug’s PK transpire within the first year of life, including a rapid
surge in renal function due to an increase in renal blood flow
within the first 2 weeks of life (21, 22). Furthermore, drug PK may
not be solely dependent on PNA, particularly in the extremely
premature neonates, because nephrogenesis, which contributes to
an increasing glomerular filtration rate in utero, requires comple-
tion by 36 weeks of gestation (21, 22).
In the final population PK model, WTKG, a marker for
growth, was assumed to be a significant covariate for CL and V. In
addition to WTKG, PMA and SCR were identified as important
covariates for CL. A maturational change in ampicillin CL was
evident by the inclusion of both PMA and SCR as covariates. The
need to account for developmental maturation using PMA (which
is composed of PNA and GA) is consistent with prior investiga-
tions of ampicillin PK in neonates that correlated drug elimina-
tion to PNA (2, 4, 8). Furthermore, SCR was expected to be
strongly correlated to CL given the predominantly renal elimina-
tion of this drug.
The population PK parameter estimate for elimination half-
life in the present study was comparable to prior reports on pre-
mature neonates, with inverse proportionality to PNA (2, 4, 8). In
our cohort of premature neonates, the median half-life ranged
from 3.2 to 5.0 h for neonates with PNAs of 7 days but decreased
to 2.4 to 4.0 h for those with PNAs of 8 and 28 days. In addi-
tion, ampicillin CL increased rapidly by 27% after the first week of
life (i.e., group 1 versus 2 with a GA of 34 weeks and group 3
versus 4 with a GA of 34 weeks). Furthermore, ampicillin CL
increased by 56% from the younger (GA of 34 weeks) to the
older (GA of 34 weeks) cohorts. Previous investigations did not
specifically provide CL and V estimates. A 1-compartment model
appropriately described our data, similar to the case in a prior
study that reported no substantial improvement in fit with a
2-compartment model compared to a 1-compartment model af-
ter intramuscular injection of ampicillin (23). Our model was pre-
cise as evidenced by population CL and V point estimates nearly
identical to the median bootstrap values and narrow 95% confi-
dence intervals. The percentage of observations outside the pre-
diction interval was higher than expected (i.e., 10%) in the VPC.
In close examination of the VPC, bias was absent, but the differ-
ence between observed and expected concentrations was likely
0 2 4 6 8 10 12 14

































FIG 3 Visual predictive check. Circles, observed concentrations (Conc); solid
line, predicted median concentration; dashed lines: 90% confidence intervals.
TABLE 6 Probability of target attainment from Monte Carlo simulations using the final pharmacokinetic model
Groupa
% of subjects meeting MIC target of:
2 g/ml 8 g/ml
50% TMICb 75% TMIC 100% TMIC 50% TMIC 75% TMIC 100% TMIC
Harriet Lane
1 100 100 100 100 100 99.8
2 100 100 100 100 100 99.8
3 100 100 98.8 100 100 90.2
4 100 100 100 100 100 99.2
Neofax
1 100 100 1 100 100 98.1
2 100 100 99.8 100 100 96.9
3 100 100 98.8 100 100 90.2
4 100 100 99.2 100 100 90.2
Typical POPS doses
1 100 100 100 100 100 99.2
2 100 100 100 100 100 97.1
3 100 100 99.6 100 100 98.1
4 100 100 100 100 100 98.3
a Group numbers refer to the age group categories defined in Table 1.
b TMIC, time above MIC.
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due to the inability to characterize the ETA for V. Furthermore,
our final PK model supported a single ETA only for CL (not V).
The small sample size in our study likely contributed to this out-
come.
The Monte Carlo simulation demonstrated that the higher
doses of ampicillin currently being prescribed by most physicians,
as evident by the average daily dose of ampicillin ordered for the
neonates in this study, achieved the surrogate PD endpoint of
trough concentrations at steady state of 8 g/ml in 97% of
virtual subjects compared to 90% of virtual subjects with the
current dosing references. Compared to the dosing regimens
recommended in pediatric references, our proposed optimal
dosing strategy for ampicillin provides fewer dosing groups,
accounts for renal function that dramatically changes within
the first few weeks of life (including preterm infants 29
weeks), and incorporates more convenient, less frequent dos-
ing (every 8 h rather than every 6 h).
This study had several strengths and limitations. We assessed
the PK of ampicillin over a broader range of GA and PNA than in
previous studies; thus, we were better able to delineate the devel-
opmental aspects associated with ampicillin. While the final pop-
ulation PK model allowed us to characterize the CL and V of
ampicillin in these preterm and term neonates, we were limited in
evaluating intrapatient variability because the average number of
samples per subject was only 2. Similarly, we did not assess the role
of drug transporters in contributing to the CL and V of ampicillin.
The expression and function of drug transporters responsible for
drug distribution and those residing in the kidney (such as the
organic anion transporters) vary with age (24). Approximately
90% of ampicillin is excreted as unchanged drug in the kidney
(18). While not examined in our study, these age-related differ-
ences in drug transporters may have contributed to ampicillin CL.
As this was an opportunistic study, we did not control for consis-
tent dosing. Doses ranged from 100 to 350 mg/kg/day and gener-
ally exceeded the recommended doses. Notably, our Monte Carlo
simulations did not account for ampicillin penetration into the
cerebrospinal fluid, which has been reported at a range of 11 to
65% based on doses of 120 to 200 mg/kg/day administered in
infants 1 month old with meningitis (8). Further studies are
needed to explore optimal dosing for the treatment of meningitis,
especially in premature infants 1 month old, for whom only one
study is currently available (8).
Conclusions. This large opportunistic population PK study of
ampicillin in neonates demonstrated the importance of PMA in
drug CL. We simplified the dosing regimens from several refer-
ences and devised an ampicillin dosing regimen of 50 to 75 mg/kg
every 8 to 12 h, based on GA and PNA (Table 7). This revised
dosing regimen achieved trough concentrations of 8 g/ml in
90% of subjects. Furthermore, although several references suggest
dosing every 6 h for some PNA and GA groups, adjusting the total
dose to allow for dosing every 8 h decreases the frequency of am-
picillin administration yet maintains therapeutic drug exposure.
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